New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor–Positive Breast Cancer
Neha Pathak, Mafalda Oliveira
Abstract
Oral selective estrogen receptor degraders (SERDs) are pure estrogen receptor antagonists that have the potential to overcome common resistance mechanisms to endocrine therapy in estrogen receptor-positive breast cancer. There are currently five oral SERDs in published and ongoing clinical trials-elacestrant, camizestrant, giredestrant, imlunestrant, and amcenestrant-with more in development. They offer a reasonably well-tolerated oral therapy option with low discontinuation rates in studies. This review summarizes the currently available literature on this new class of drugs.
Topics & Concepts
Estrogen receptorEstrogenBreast cancerMedicineSelective estrogen receptor modulatorDiscontinuationEndocrine systemEstrogen-related receptor alphaEstrogen receptor betaCancerPharmacologyCancer researchInternal medicineBioinformaticsHormoneBiologyEstrogen and related hormone effectsAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer Research